This review highlights the potential of phosphorodiamidate morpholino oligomers (PMOs) as a versatile and effective class of antiviral therapeutics against a broad spectrum of RNA viruses.
No takes yet. Share an insight, caveat, or question.
PMO antivirals merit clinical translation studies; leaves open human efficacy and safety pending prospective trials.
Nan et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: